SAN DIEGO, Aug. 26 /PRNewswire-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) today issued the following letter to all shareholders.
To all shareholders and supporters of Imagenetix, Inc.: the purpose of this letter is to update you on activities at the company. It is my intention to provide periodic communication to our shareholders through these letters as a means to provide insight to you on topical issues and to provide a uniform status report on activities at the company.
I am delighted to share with you that fiscal 2009, the twelve months ended March 31, 2009, was a pivotal year for your company. First, we enjoyed continued scientific achievements; second, we expanded the distribution of our flag-ship branded product, InflameAway Celadrin(R); and, third, as we enter the new fiscal year, we will be introducing a new innovative product, BioGuard(TM). In addition, we continue to position our fat loss product.
The results of a second study conducted on our proprietary compound, 1-TDC, for the treatment of periodontal disease has been published in the July issue of The Journal of Periodontology and is also available online at: http://www.joponline.org/loi/jop (J Periodontal 2009; 80(7):1103-13).
In the recent study, 1-TDC was applied to the gum line using the rabbit periodontitis model developed by Boston University investigators. The study results show that 1-TDC stopped the progression of periodontal disease with a significant improvement and restoration in tissue and bone health compared to the placebo group.
We now have two published animal studies showing clear evidence of efficacy and we continue to position our 1-TDC for a phase 1 trial with the FDA. In addition, we anticipate receiving news shortly on our patent associated with this compound. We also have contracted with an internationally respected Clinical Research Organization (CRO) to provide Imagenetix specific time lines to achieve drug approval from the FDA.
InflameAway Celadrin(R) extra strength soft gels for joint health are currently available at the nation's number one drug chain, the number one and number two supermarket stores and the number one club warehouse store. This retail distribution provides a platform for future retail gains as well as additional product launches, including a 100 count value size.
We have recently expanded our successful 15 and 30 second television ad spots for InflameAway Celadrin(R) to national audiences via cable as the primary driver of retail turnover. Starting August 10th, InflameAway Celadrin(R) can be seen on networks such as FOX news, CNN, USA and Hallmark. The spots will emphasize the theme of InflameAway Celadrin(R) being "6x Faster and More Effective" than Glucosamine and Chondroitin in promoting joint health. The campaign will also include compelling "actual user" testimonials as further evidence of brand performance and efficacy. This consumer campaign is intended to position InflameAway Celadrin(R) for rapid acceptance during the balance of this year and into 2010 - with the goal of obtaining loyal advocates of InflameAway Celadrin(R). Repeat customers, product compliance and beneficial results are core strengths of the InflameAway Celadrin(R) brand.
You can view these television spots by following these links:
We have just received regional "in club" orders from the largest U.S. club warehouse for our most recent product, BioGuard(TM). BioGuard(TM) is a clinically proven pro-biotic uniquely designed for ear, nose, throat and immune system protection. This new innovative brand is designed to provide around the clock natural protection of the ear, nose and throat, the gateway to many illnesses. The strawberry flavored chewable tablet can be taken by all family members. If you live in the Pacific Northwest, you will be able to purchase BioGuard(TM) at the area's leading club warehouses starting in the beginning of October. Assuming a successful regional test, a nationwide launch could start as early as the first calendar quarter of 2010.
Fat Loss Product
Our intellectually protected, clinically proven, private label fat loss product has the potential to expand on a global basis. We sponsored clinical studies at the University of Minnesota and the University of Connecticut and have been recently published in the prestigious journal - The European Journal of Applied Physiology. This product offers us a unique opportunity to make a positive impact on the global problem associated with obesity.
New innovations in product and science are exciting but it is truly gratifying to see acceptance and the beginning stages of success of our products in the mass market, particularly the exciting opportunities in the top club warehouse. We have diligently focused our efforts and are now well positioned to prospectively post solid growth with our proprietary branded products.
It goes without saying that this past year has brought about financial turmoil amongst nearly all companies, both large and small. Through wise financial management, Imagenetix has been able to achieve extraordinary scientific progress and product brand expansion.
Admittedly, unprecedented accomplishments in new products and scientific discoveries do take time, but the potential return of future rewards can be dramatically positive. Imagenetix has made these great strides while maintaining sound financial principles. Imagenetix has a proven track record of investing wisely and internally, without the requirement of issuing more stock or incurring any debt. In fact, Imagenetix has been in a debt free position now for quite some time. In this past fiscal year, your company achieved sales growth and was profitable. These near magical accomplishments could not have been attained without the committed, talented and experienced Imagenetix staff, consultants and associates. My enthusiasm remains high while we experience the numerous opportunities for success with our recent technological advancements.
Our strategic focus on the development of scientifically innovative and technologically advanced products, whether in the nutritional or pharmaceutical segment, is a competitive strength of your company. Our unparalleled commitment for product and scientific excellence has begun to pay off. While we are pleased with the beginnings of sound performance and expansion, we are also focused on delivering long term and sustainable shareholder value while continuing to make sound decisions that seek to achieve high levels of growth and superior returns in the long term.
As always, our goal has been to appropriately grow your company's business in a financially responsible manner based on strategic logic. Continued clinical studies are just another example of being dedicated to effectively expanding and positioning our products around the world.
In summation, and on behalf of the Imagenetix organization, I wish to thank you for your past support and pledge our dedication to you, our valued shareholders, for continued future successes.
/s/ William P. Spencer
William P. Spencer
Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected. Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services. Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2009.
Contact Imagenetix Investor Relations William P. Spencer (858)385-2797 Chief Executive Officer Imagenetix, Inc. Tel: (858) 674-8455
|SOURCE Imagenetix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved